706 Participants Needed

Brain Safe App for Alzheimer's Disease

Recruiting at 2 trial locations
KT
CV
Overseen ByChristian Vallejo, BS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Indiana University
Must be taking: Anticholinergics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.

Research Team

RJ

Richard J Holden, PhD

Principal Investigator

Indiana University School of Medicine

Eligibility Criteria

This trial is for adults over 60 in Central Indiana who are English-speaking, have had a primary care visit within the last year, and are currently prescribed strong anticholinergic medications. They must not be cognitively impaired, terminally ill, or living in extended care facilities. Those with Alzheimer's disease or severe mental health conditions like schizophrenia cannot participate.

Inclusion Criteria

You do not have impaired senses, even with correction like glasses or hearing aids.
English-speaking
I am 60 years old or older.
See 7 more

Exclusion Criteria

I have been diagnosed with Alzheimer's or a similar type of dementia.
I have been diagnosed with schizophrenia, bipolar disorder, or schizoaffective disorder.
You have a condition that makes it difficult for you to use a mobile touchscreen device or participate in the study activities, even with help.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders

12 months
Monthly electronic data capture

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Treatment Details

Interventions

  • Attention Control App
  • Brain Safe App
Trial Overview The study tests if the Brain Safe app can reduce exposure to drugs linked to Alzheimer's when used by older adults taking anticholinergics. Participants will either use this app or a control medication list app for one year with monthly reminders.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Brain Safe AppExperimental Treatment1 Intervention
1)Brain Safe App provides conversation starters for older adult patients on target anticholinergics. The conversation starters assist the patient to have discussions with their physicians regarding reduction in exposure to prescription anticholinergics. 2) Provides anticholinergic risk assessment.
Group II: Attention Control AppPlacebo Group1 Intervention
1) Attention Control App provides a medication list for older patients to use but lacks the conversation starters for patient to use with there physicians aimed at reduction in exposure to prescription anticholinergics.2) No anticholinergic risk assessment.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Indiana University

Lead Sponsor

Trials
1,063
Recruited
1,182,000+

National Institute on Aging (NIA)

Collaborator

Trials
1,841
Recruited
28,150,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security